AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
hymecromone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 1401 | 90-33-5 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A coumarin derivative possessing properties as a spasmolytic, choleretic and light-protective agent. It is also used in ANALYTICAL CHEMISTRY TECHNIQUES for the determination of NITRIC ACID.
|
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 1.998 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 1.750 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 50.466 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 66.527 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 14.920 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 21.090 | % | High | 1 |
| herg | hERG pIC50 | 4.567 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 169.434 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 27.102 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 7.170 | % | High | 1 |
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,AKT2,AKT3,ALK,AURKA,AURKB,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK1,CDK2,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3B,IKBKB,ITK,JAK1,JAK2,KIT,MAP2K6,MAP3K1,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAPK1,MAPK10,MAPK12,MAPK7,MAPK9,MAPKAPK2,MAPKAPK5,MARK4,MET,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM1,PIM2,PRKCD,PRKDC,SGK1,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ULK2,ZAP70 | 72 | |||
| kinase-selectivity-class | ACVR2A,ACVR2B,AXL,CDK9,DYRK1B,GRK2,MAP2K6,MAPK7,PRKDC,STK33,TEK,TTK | 12 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 7.413 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 374.111 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 22.790 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 3.365 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 12.600 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 358.922 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 82.820 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 10.030 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 238.781 | uM | High | 1 |
Approvals:
None
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A05AX02 | ALIMENTARY TRACT AND METABOLISM BILE AND LIVER THERAPY BILE THERAPY Other drugs for bile therapy |
| MeSH PA | D007202 | Indicators and Reagents |
| CHEBI has role | CHEBI:35610 | antineoplastic agents |
| CHEBI has role | CHEBI:131561 | HA synthesis inhibitor |
Related Drugs by ATC class:
A05AX Other drugs for bile therapy 6 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 8.16 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Amine oxidase [flavin-containing] B | Enzyme | IC50 | 4.09 | CHEMBL | |||||
| Aldose reductase | Enzyme | IC50 | 4.61 | CHEMBL | |||||
| Carbonic anhydrase 9 | Enzyme | Ki | 6.25 | CHEMBL | |||||
| Carbonic anhydrase 12 | Enzyme | Ki | 5.09 | CHEMBL | |||||
| Induced myeloid leukemia cell differentiation protein Mcl-1 | Cytosolic other | Ki | 4.66 | CHEMBL | |||||
| Testosterone 17-beta-dehydrogenase 3 | Enzyme | IC50 | 6 | CHEMBL | |||||
| Aldose reductase | Enzyme | IC50 | 4.21 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| N0000167012 | NUI |
| D00170 | KEGG_DRUG |
| C0020411 | UMLSCUI |
| CHEBI:17224 | CHEBI |
| 4MU | PDB_CHEM_ID |
| CHEMBL12208 | ChEMBL_ID |
| DB07118 | DRUGBANK_ID |
| D006923 | MESH_DESCRIPTOR_UI |
| 5280567 | PUBCHEM_CID |
| 1891 | INN_ID |
| 3T5NG4Q468 | UNII |
| 5556 | RXNORM |
| 005482 | NDDF |
Pharmaceutical products:
None